

Tokyo, Jun, 16, 2026

FOR IMMEDIATE RELEASE

**Announcement of First Dosing in Phase 3 Clinical Study of YCANTH®/TO-208
for the Treatment of Common Warts**

Torii Pharmaceutical Co., Ltd. (Torii) entered into a Collaboration and License Agreement on March 17, 2021, with Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, with respect to the exclusive development and commercialization of Verrica's skin disease treatment drug VP-102 (Product name in the United States: YCANTH®, hereinafter "TO-208") for the treatment of molluscum contagiosum and common warts in Japan. As previously announced, Torii and Verrica are currently developing the product for patients with common warts. We are pleased to announce that, in the ongoing global Phase 3 clinical program studying TO-208 for patients with common warts, the first subject in Japan has been enrolled and received the initial dose.

Common warts (*Verruca vulgaris*) are a common dermatologic disease caused by infection with the human papillomavirus (HPV), commonly known as "warts". They typically appear keratinized, raised bumps (several mm to 1 cm) on the hands and feet.

TO-208 is a topical solution for the treatment of viral warts that uses cantharidin as its active ingredient. It is thought that when TO-208 is applied to the affected area, it activates neutral serine proteases, weakening epidermal desmosomes of the epidermis and breaks down the epidermal structure, and leading to the formation of intraepidermal blisters at the application site. The formation of these blisters causes the affected skin to peel off. The resulting peeling of the skin is believed to remove the virus-infected tissue, thereby providing a therapeutic effect.

This clinical study is a double-blind, randomized, parallel-group, placebo-controlled study evaluating the efficacy and safety of TO-208 when applied once daily every 21 days for a total of up to four applications in patients (≥2 years old) with common warts. Based on the results of this trial, we intend to seek marketing approval in Japan.

In the United States, Verrica received approval for YCANTH® from the U.S. Food and Drug Administration in July 2023 for the topical treatment of molluscum contagiosum in adult and pediatric patients (≥2 years old) and launched this product in the US in August 2023. Torii received manufacturing and marketing approval for YCANTH® for the topical treatment of molluscum contagiosum in September 2025 and launched this product in February 2026.

In addition, Verrica is currently conducting the global Phase 3 clinical program in adult and pediatric patients (≥2 years old) with common warts for YCANTH® in the United States, with the first patient

dosed in December 2025, and recently reported in May 2026 that the first clinical study in the program has now achieved more than 50% of current targeted enrollment in that study.

Contact for Torii Pharmaceutical Co., Ltd.:
Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814
E-mail: webmaster@torii.co.jp